Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

0.4071 -0.0917 (-18.38%)
Delayed Quote Updated: 4:00 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
US Top Movers: Small-Cap Gainers and Losers in Today's Session ↗
Via Chartmill
US Top Movers: Gainers and Losers for Nov. 3, 2026 ↗
Via Chartmill
US Stock Gap Movers: Up and Down Names in Today's Session ↗
Via Chartmill
Premarket Movers: Gainers and Losers Ahead of November 3, 2026 U.S. Open ↗
Via Chartmill
US Session Top Gainers and Losers Led by INLF and AUROW ↗
Via Chartmill
Small-Cap Market Movers: Top Gainers and Losers on Nov. 2, 2026 ↗
Via Chartmill
US Gap Movers: Top Gap-Up and Gap-Down Stocks in Today's Session ↗
Via Chartmill
News headline image
CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) for crofelemer... 
From Jaguar Health, Inc.
Via ACCESS Newswire
Premarket Movers Nov. 2, 2026: Gainers and Losers ↗
Via Chartmill
News headline image
Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder
Mutation of the GUCY2C gene is the third IF-related congenital enteropathy, in addition to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), for which crofelemer has demonstrated... 
From Jaguar Health, Inc.
Via ACCESS Newswire
These stocks that are showing activity before the opening bell on Friday. ↗
Via Chartmill
News headline image
Jaguar Health Provides Update Regarding Special Stock Dividend
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives Jaguar's rare disease intestinal failure development program for... 
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for SBS-IF and microvillus inclusion disease (MVID) for crofelemer powder for oral solution,... 
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives Jaguar's rare disease intestinal failure development program for... 
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and short bowel syndrome (SBS) for crofelemer powder... 
From Jaguar Health, Inc.
Via ACCESS Newswire
What's going on in today's pre-market session ↗
Via Chartmill
Keep an eye on the top gainers and losers in Monday's session. ↗
Via Chartmill
News headline image
Jaguar Health Announces a Special Stock Dividend
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives 
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS-IF for crofelemer powder for oral solution,... 
From Jaguar Health, Inc.
Via ACCESS Newswire
Gapping stocks in Friday's session ↗
Via Chartmill
Unusual volume stocks in Thursday's session ↗
Via Chartmill
The market is filled with gapping stocks in Thursday's session. ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Wednesday's session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Wednesday's session ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
These stocks are moving in today's after hours session ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
News headline image
Jaguar Health Receives Fee Waivers from FDA
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution,... 
From Jaguar Health, Inc.
Via ACCESS Newswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.